NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
In This Article:
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
The pivotal trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control.
In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; P=0.039) (N=571).
The survival rate benefit for patients treated with TTFields therapy increased over time, with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months.
TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets. Zai Lab plans to file for regulatory approval in China.
Novocure continues to follow patients in its Phase 2 PANOVA-4 trial, which is exploring the use of TTFields therapy together with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment, and data are anticipated in 2026.
Price Action: NVCR stock is up 31% at $26.26 at last check Monday.
Read Next:
Photo via Shutterstock.
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.